The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder

Bing Cao, Caroline Park, Mehala Subramaniapillai, Yena Lee, Michelle Iacobucci, Rodrigo B Mansur, Hannah Zuckerman, Lee Phan, Roger S McIntyre, Bing Cao, Caroline Park, Mehala Subramaniapillai, Yena Lee, Michelle Iacobucci, Rodrigo B Mansur, Hannah Zuckerman, Lee Phan, Roger S McIntyre

Abstract

Background: Anhedonia is a common, persistent, and disabling phenomenon in treated adults with Major Depressive Disorder (MDD). Hitherto, relatively few antidepressant agents have been evaluated with respect to their effect on anhedonia in MDD. Methods: This is a post-hoc analysis of a primary study that sought to evaluate the sensitivity to change of the THINC-integrated tool (THINC-it) in MDD (ClinicalTrials.gov Identifier: NCT03053362). Adults meeting DSM-5 criteria for MDD with at least moderate depressive symptom severity [i.e., Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥20] were eligible. Subjects were recruited between October 2017 and August 2018 in Toronto, Ontario at the Brain and Cognition Discovery Foundation. All subjects received open-label vortioxetine (10-20 mg/day, flexibly-dosed) for 8 weeks. Herein, the primary outcome of interest was the change from baseline to endpoint in the Snaith-Hamilton Pleasure Scale (SHAPS) total score, as well as the MADRS anhedonia factor. The mediational effects of improvements in anhedonia on general function and quality of life, as measured by the Sheehan Disability Scale (SDS) and the 5-Item World Health Organization Well-Being Index (WHO-5), were secondarily assessed. Results: A total of 100 subjects with MDD were enrolled in the primary study and began treatment with vortioxetine. Vortioxetine significantly improved anhedonia as evidenced by significant baseline to endpoint improvements in SHAPS and MADRS anhedonia factor scores (p < 0.0001). Improvements in the SHAPS and the MADRS anhedonia factor correlated with improvements in general function (i.e., SDS) and quality of life (i.e., WHO-5) (p < 0.0001). Notably, improvements in anhedonia were found to mediate the association between improvements in overall depressive symptom severity (i.e., MADRS total score) and social functioning (i.e., social life component of the SDS) (p = 0.026). Conclusion: The unmet need in depression is to improve patient functioning and other patient-reported outcomes (e.g., quality of life). Antidepressant interventions capable of attenuating anhedonia as well as cognitive dysfunction in MDD may help in this regard, as improvement in these domains have been associated with improvement in psychosocial function and quality of life.

Keywords: anhedonia; antidepressants; function; major depressive disorder; quality of life; vortioxetine.

Figures

Figure 1
Figure 1
Response and remission rate of anhedonia in patients with MDD using SHAPS at weeks 2 and 8.
Figure 2
Figure 2
Mediation analysis to estimate indirect effects of anhedonia improvement (ΔSHAPS) in the improvement of depressive symptoms (ΔMADRS) and function (ΔSDS). a, b, and c are path coefficients. (A) SDS total score, (B) SDS- work/school; (C) SDS -social life; (D) SDS-family life or home responsibilities. MADRS, Montgomery Åsberg Depression Rating Scale; SHAPS, Snaith-Hamilton Pleasure Scale; SDS, Sheehan Disability Scale.
Figure 3
Figure 3
Mediation analysis to estimate indirect effects of anhedonia improvement (ΔSHAPS) in the improvement of depressive symptoms (ΔMADRS) and well-being (ΔWHO-5). a, b, and c are path coefficients. MADRS, Montgomery Åsberg Depression Rating Scale; SHAPS, Snaith-Hamilton Pleasure Scale; WHO-5, The World Health Organization- Five Well-Being Index.

References

    1. Vos T, Abajobir A, Abbafati C, Abbas K, Abate K, Abd-Allah F. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (2017) 390:1211–59. 10.1016/S0140-6736(17)32154-2
    1. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry (2015) 76:155–62. 10.4088/JCP.14m09298
    1. Woo YS, Rosenblat JD, Kakar R, Bahk WM, McIntyre RS. Cognitive deficits as a mediator of poor occupational function in remitted major depressive disorder patients. Clin Psychopharmacol Neurosci. (2016) 14:1–16. 10.9758/cpn.2016.14.1.1
    1. APA Diagnostic and Statistical Manual of Mental Disorder. 5th ed. American Psychiatric Association; (2013). 10.1176/appi.books.9780890425596
    1. NIMH Definitions of the RDoC Domains and Constructs (2018). Available online at:
    1. Pan Z, Rosenblat JD, Swardfager W, McIntyre RS. Role of proinflammatory cytokines in dopaminergic system disturbances, implications for anhedonic features of MDD. Curr Pharm Des. (2017) 23:2065–72. 10.2174/1381612823666170111144340
    1. Franken IH, Rassin E, Muris P. The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS). J Affect Disord. (2007) 99:83–9. 10.1016/j.jad.2006.08.020
    1. Buckner JD, Joiner TE, Jr, Pettit JW, Lewinsohn PM, Schmidt NB. Implications of the DSM's emphasis on sadness and anhedonia in major depressive disorder. Psychiatry Res. (2008) 159:25–30. 10.1016/j.psychres.2007.05.010
    1. Van Roekel E, Vrijen C, Heininga VE, Masselink M, Bos EH, Oldehinkel AJ. An exploratory randomized controlled trial of personalized lifestyle advice and tandem skydives as a means to reduce anhedonia. Behav Ther. (2017) 48:76–96. 10.1016/j.beth.2016.09.009
    1. Di Giannantonio M, Martinotti G. Anhedonia and major depression: the role of agomelatine. Eur Neuropsychopharmacol. (2012) 22 (Suppl. 3):S505–10. 10.1016/j.euroneuro.2012.07.004
    1. Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate CA, Jr. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol. (2015) 29:596–607. 10.1177/0269881114568041
    1. Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf. (2015) 14:1291–304. 10.1517/14740338.2015.1046836
    1. McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. (2016) 19:pyw055 10.1093/ijnp/pyw055
    1. McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat. (2017) 13:2913–9. 10.2147/NDT.S150589
    1. Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders. J Affect Disord. (2018) 227:787–94. 10.1016/j.jad.2017.11.081
    1. Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry (2014) 14:276. 10.1186/s12888-014-0276-x
    1. Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord. (2016) 206:140–50. 10.1016/j.jad.2016.07.015
    1. Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. (2016) 26:979–93. 10.1016/j.euroneuro.2016.03.007
    1. Vinckier F, Gourion D, Mouchabac S. Anhedonia predicts poor psychosocial functioning: results from a large cohort of patients treated for major depressive disorder by general practitioners. Eur Psychiatry (2017) 44:1–8. 10.1016/j.eurpsy.2017.02.485
    1. Satterthwaite TD, Kable JW, Vandekar L, Katchmar N, Bassett DS, Baldassano CF, et al. . Common and dissociable dysfunction of the reward system in bipolar and unipolar depression. Neuropsychopharmacology (2015) 40:2258–68. 10.1038/npp.2015.75
    1. Argyropoulos SV, Nutt DJ. Anhedonia revisited: is there a role for dopamine-targeting drugs for depression? J Psychopharmacol. (2013) 27:869–77. 10.1177/0269881113494104
    1. Gargoloff PD, Corral R, Herbst L, Marquez M, Martinotti G, Gargoloff PR. Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study. Hum Psychopharmacol. (2016) 31:412–8. 10.1002/hup.2557
    1. Di Giannantonio M, Di Iorio G, Guglielmo R, De Berardis D, Conti CM, Acciavatti T, et al. . Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents (2011) 25:109–14. 10.1016/S0924-9338(11)72356-2
    1. Martinotti G, Sepede G, Gambi F, Di Iorio G, De Berardis D, Di Nicola M, et al. . Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol. (2012) 32:487–91. 10.1097/JCP.0b013e31825d6c25
    1. Martinotti G, Pettorruso M, De Berardis D, Varasano PA, Lucidi Pressanti G, De Remigis V, et al. . Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms. Int J Neuropsychopharmacol. (2016) 19:pyw003. 10.1093/ijnp/pyw003
    1. Burstein O, Franko M, Gale E, Handelsman A, Barak S, Motsan S, et al. . Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. PLoS ONE (2017) 12:e0188043. 10.1371/journal.pone.0188043
    1. Corruble E, de Bodinat C, Belaidi C, Goodwin GM, agomelatine study group . Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. (2013) 16:2219–34. 10.1017/S1461145713000679
    1. Hatzigiakoumis DS, Martinotti G, Giannantonio MD, Janiri L. Anhedonia and substance dependence: clinical correlates and treatment options. Front Psychiatry (2011) 2:10. 10.3389/fpsyt.2011.00010
    1. Feingold D, Rehm J, Lev-Ran S. Cannabis use and the course and outcome of major depressive disorder: a population based longitudinal study. Psychiatry Res. (2017) 251:225–34. 10.1016/j.psychres.2017.02.027
    1. Bogdan R, Nikolova YS, Pizzagalli DA. Neurogenetics of depression: a focus on reward processing and stress sensitivity. Neurobiol Dis. (2013) 52:12–23. 10.1016/j.nbd.2012.05.007
    1. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N. Remission in depressed outpatients: more than just symptom resolution? J Psychiatr Res. (2008) 42:797–801. 10.1016/j.jpsychires.2007.09.004
    1. Lee Y, Rosenblat JD, Lee J, Carmona NE, Subramaniapillai M, Shekotikhina M, et al. . Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: a systematic review. J Affect Disord. (2018) 227:406–15. 10.1016/j.jad.2017.11.003
    1. McIntyre RS, Lee Y, Mansur RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr. (2015) 20(Suppl. 1):20–30. 10.1017/S1092852915000826
    1. Christensen MC, Loft H, Florea I, McIntyre RS. Efficacy of vortioxetine in working patients with generalized anxiety disorder. CNS Spectr. (2017) 1–9. 10.1017/S1092852917000761. [Epub ahead of print].
    1. Wang J, Liu XF, Feng C, Bao Q, Fu HR. Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study. Int J Psychiatry Clin Pract. (2017) 1–6. 10.1080/13651501.2017.1397700. [Epub ahead of print].
    1. Treadway MT, Buckholtz JW, Schwartzman AN, Lambert WE, Zald DH. Worth the 'EEfRT'? The effort expenditure for rewards task as an objective measure of motivation and anhedonia. PLoS ONE (2009) 4:e6598. 10.1371/journal.pone.0006598

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe